JP2021512099A5 - - Google Patents

Info

Publication number
JP2021512099A5
JP2021512099A5 JP2020541689A JP2020541689A JP2021512099A5 JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5 JP 2020541689 A JP2020541689 A JP 2020541689A JP 2020541689 A JP2020541689 A JP 2020541689A JP 2021512099 A5 JP2021512099 A5 JP 2021512099A5
Authority
JP
Japan
Prior art keywords
group
ttds
palm
amino acid
stea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512099A (ja
JP7295871B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/052298 external-priority patent/WO2019149782A1/en
Publication of JP2021512099A publication Critical patent/JP2021512099A/ja
Publication of JP2021512099A5 publication Critical patent/JP2021512099A5/ja
Application granted granted Critical
Publication of JP7295871B2 publication Critical patent/JP7295871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541689A 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 Active JP7295871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094.7 2018-01-31
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2021512099A JP2021512099A (ja) 2021-05-13
JP2021512099A5 true JP2021512099A5 (cg-RX-API-DMAC7.html) 2022-02-02
JP7295871B2 JP7295871B2 (ja) 2023-06-21

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541689A Active JP7295871B2 (ja) 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用

Country Status (29)

Country Link
US (3) US10961295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746467B1 (cg-RX-API-DMAC7.html)
JP (1) JP7295871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755938B1 (cg-RX-API-DMAC7.html)
CN (1) CN111770934B (cg-RX-API-DMAC7.html)
AR (1) AR114325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019214358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089657A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008308A2 (cg-RX-API-DMAC7.html)
DK (1) DK3746467T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058633T3 (cg-RX-API-DMAC7.html)
FI (1) FI3746467T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260016T1 (cg-RX-API-DMAC7.html)
IL (2) IL276170B2 (cg-RX-API-DMAC7.html)
LT (1) LT3746467T (cg-RX-API-DMAC7.html)
MA (1) MA52994A (cg-RX-API-DMAC7.html)
MX (1) MX2020008096A (cg-RX-API-DMAC7.html)
MY (1) MY199821A (cg-RX-API-DMAC7.html)
NZ (1) NZ766762A (cg-RX-API-DMAC7.html)
PH (1) PH12020551118A1 (cg-RX-API-DMAC7.html)
PL (1) PL3746467T3 (cg-RX-API-DMAC7.html)
PT (1) PT3746467T (cg-RX-API-DMAC7.html)
RS (1) RS67606B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006903WA (cg-RX-API-DMAC7.html)
SI (1) SI3746467T1 (cg-RX-API-DMAC7.html)
TW (1) TWI763972B (cg-RX-API-DMAC7.html)
UY (1) UY38069A (cg-RX-API-DMAC7.html)
WO (1) WO2019149782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Similar Documents

Publication Publication Date Title
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP2013500990A5 (cg-RX-API-DMAC7.html)
EP2858661B1 (en) Stabilized antiviral fusion helices
JP2020502051A5 (cg-RX-API-DMAC7.html)
JP6633523B2 (ja) Psd−95の二量体阻害剤脂肪酸誘導体
JP2010535714A5 (cg-RX-API-DMAC7.html)
JP2015533833A5 (cg-RX-API-DMAC7.html)
JP2024532403A5 (cg-RX-API-DMAC7.html)
JP2022551282A5 (cg-RX-API-DMAC7.html)
IL275188B1 (en) Use of cyclic tripeptide to improve cellular energy metabolism
JP2012531219A5 (cg-RX-API-DMAC7.html)
JP2015534972A5 (cg-RX-API-DMAC7.html)
JP2025172864A5 (cg-RX-API-DMAC7.html)
JP2023551122A5 (cg-RX-API-DMAC7.html)
JP2024532403A (ja) 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ
JP2020515283A5 (cg-RX-API-DMAC7.html)
JP2018536645A5 (cg-RX-API-DMAC7.html)
JP2021533128A5 (cg-RX-API-DMAC7.html)
CN1041524C (zh) 由c-活性蛋白质片段衍生的寡肽及其药物组合物
JP2018507187A5 (cg-RX-API-DMAC7.html)
JP2024539138A5 (cg-RX-API-DMAC7.html)
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2022515721A5 (cg-RX-API-DMAC7.html)
JP2009507077A5 (cg-RX-API-DMAC7.html)
US10092620B2 (en) Uses of cyclic peptides for treating and preventing atherosclerosis